JP2024516003A - 糖尿病網膜症および関連する状態を治療するための方法および組成物 - Google Patents

糖尿病網膜症および関連する状態を治療するための方法および組成物 Download PDF

Info

Publication number
JP2024516003A
JP2024516003A JP2023566803A JP2023566803A JP2024516003A JP 2024516003 A JP2024516003 A JP 2024516003A JP 2023566803 A JP2023566803 A JP 2023566803A JP 2023566803 A JP2023566803 A JP 2023566803A JP 2024516003 A JP2024516003 A JP 2024516003A
Authority
JP
Japan
Prior art keywords
therapeutic agent
patient
orally administered
certain embodiments
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516003A5 (enExample
Inventor
スーチ，ミナ
チャリザニス，コンスタンティノス
アール ケリー，マーク
アダム メスマン，リチャード
ジョージ ブリゲル，ミッチェル
アジャイクマール パテル，ロニール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Ocuphire Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocuphire Pharma Inc filed Critical Ocuphire Pharma Inc
Publication of JP2024516003A publication Critical patent/JP2024516003A/ja
Publication of JP2024516003A5 publication Critical patent/JP2024516003A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023566803A 2021-04-30 2022-04-29 糖尿病網膜症および関連する状態を治療するための方法および組成物 Pending JP2024516003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182037P 2021-04-30 2021-04-30
US63/182,037 2021-04-30
PCT/US2022/027062 WO2022232597A1 (en) 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions

Publications (2)

Publication Number Publication Date
JP2024516003A true JP2024516003A (ja) 2024-04-11
JP2024516003A5 JP2024516003A5 (enExample) 2025-05-09

Family

ID=83848745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566803A Pending JP2024516003A (ja) 2021-04-30 2022-04-29 糖尿病網膜症および関連する状態を治療するための方法および組成物

Country Status (11)

Country Link
US (1) US20240216315A1 (enExample)
EP (1) EP4329741A4 (enExample)
JP (1) JP2024516003A (enExample)
KR (1) KR20240049212A (enExample)
CN (1) CN117500492A (enExample)
AU (1) AU2022264037A1 (enExample)
BR (1) BR112023022561A2 (enExample)
CA (1) CA3217136A1 (enExample)
IL (1) IL308083A (enExample)
MX (1) MX2023012793A (enExample)
WO (1) WO2022232597A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4587003A2 (en) 2022-09-14 2025-07-23 Opus Genetics, Inc. Salts and esters of apx3330 and therapeutic uses thereof
WO2024158972A1 (en) * 2023-01-25 2024-08-02 Ocuphire Pharma, Inc. Methods and compositions for preventing the progression of diabetic retinopathy and related conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540544A (ja) * 2007-09-26 2010-12-24 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 癌および血管新生の治療のための、化学療法剤と組み合わせたベンゾキノン誘導体ｅ３３３０

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019218797B2 (en) * 2018-02-08 2023-09-21 Indiana University Research And Technology Corporation Targeting ocular diseases with novel APE1/Ref-1 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540544A (ja) * 2007-09-26 2010-12-24 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 癌および血管新生の治療のための、化学療法剤と組み合わせたベンゾキノン誘導体ｅ３３３０

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy (ZETA-1)", U.S. NATIONAL LIBRARY OF MEDICINE, CLINICALTRIALS.GOV, NCT04692688, JPN7026000478, ISSN: 0005793423 *
SHEIK PRAN BABU SARDAR PASHA ET AL.: "Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. Volume 367, Issue 1, JPN7026000477, October 2018 (2018-10-01), pages 108 - 118, ISSN: 0005793424 *
XIAOXI QIAO ET AL.: "APE1/Ref-1 redox inhibitor APX3330 modulates choroidal endothelial cells by transcriptional regulati", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. Volume 54, Issue15, JPN7026000476, June 2013 (2013-06-01), ISSN: 0005793425 *

Also Published As

Publication number Publication date
BR112023022561A2 (pt) 2024-01-02
MX2023012793A (es) 2024-01-11
US20240216315A1 (en) 2024-07-04
CA3217136A1 (en) 2022-11-03
CN117500492A (zh) 2024-02-02
IL308083A (en) 2023-12-01
AU2022264037A1 (en) 2023-11-16
EP4329741A4 (en) 2025-01-08
EP4329741A1 (en) 2024-03-06
WO2022232597A1 (en) 2022-11-03
KR20240049212A (ko) 2024-04-16

Similar Documents

Publication Publication Date Title
KR100723189B1 (ko) 눈에 국소적으로 사용하기 위한 브리모니딘과 티몰롤의조합물
EP3302379B1 (en) Compositions and methods for treating pterygium
JP5341933B2 (ja) 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
CN115697333A (zh) 包含阿西替尼的组合物和治疗眼部疾病的方法
US20240216315A1 (en) Methods and compositions for treatment of diabetic retinopathy and related conditions
AU2024204716A1 (en) Treatment of alopecia areata
US20050043220A1 (en) Methods and compositions for treating macular degeneration
US20240148709A1 (en) Methods of treating eye pain and eye disorders
US20260108483A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
US20240252497A1 (en) Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
WO2025072687A1 (en) Methods and compositions for treatment of geographic atrophy
JP2024518787A (ja) 全身型重症筋無力症の処置のための補体因子ｄ阻害剤の使用
HK1253895B (en) Compositions and methods for treating pterygium
HK1135038B (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
HK1135038A1 (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210